Sugi Predict

Sugi Predict / Compounds / SCHEMBL19253477

SCHEMBL19253477

SCHEMBL19253477

Cc1c(C(=O)O)nn2cc(-c3cnn(C)c3)nc(O)c12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.46
▸ JAK1 P23458 4/20 0.38
▸ JAK3 P52333 4/20 0.38
▸ JAK2 O60674 3/20 0.38
▸ TYK2 P29597 3/20 0.38
▸ PIM1 P11309 1/20 0.36
▸ PIM2 Q9P1W9 1/20 0.36
▸ IRAK4 Q9NWZ3 2/20 0.35
▸ RET P07949 2/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ CCNC P24863 1/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ BTK Q06187 2/20 0.34
▸ S1PR2 O95136 1/20 0.34
▸ PLAU P00749 1/20 0.33
▸ STING1 Q86WV6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19253531 0.85 ADORA3 (0.38) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL21872223 0.81 CHEK1 (0.41) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL19253538 0.75 JAK2 (0.47) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL17801236 0.74 CHEK1 (0.47) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL24438294 0.71 CHEK1 (0.40) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL19253504 0.70 JAK2 (0.48) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL19300145 0.70 JAK2 (0.35) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL21872222 0.69 CHEK1 (0.39) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL24437890 0.68 JAK2 (0.38) CHEK1JAK1JAK3JAK2TYK2
SCHEMBL24438390 0.68 CHEK1 (0.38) CHEK1JAK1JAK3JAK2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
CN-109071546-B Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors 辉瑞大药厂 2021-03-02 — — CN disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
EP-3419978-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2020-04-15 — — EP disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
EP-3419978-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2019-01-02 — — EP disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 CHEK1 1910/4885JAK1 1320/4885JAK3 1007/4885
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 CHEK1 2027/4885JAK1 1401/4885JAK3 1062/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 CHEK1 506/4885JAK1 1/4885JAK3 3/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 CHEK1 2027/4885JAK1 1401/4885JAK3 1062/4885
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CBR1 CHEK1 1910/4885JAK1 1320/4885JAK3 1007/4885
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 CHEK1 2027/4885JAK1 1401/4885JAK3 1062/4885
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives SYMPK, IL15, STAT6 CHEK1 4154/4885JAK1 27/4885JAK3 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.